VG201 is the first product candidate built with our next generation Translational and Transcriptional Dual Regulated (TTDR) HSV-1 backbone and is uniquely engineered to enhance tumor-specific replication and payload expression without compromising safety. The two critical mechanisms of action of VG201 are the CEA promoter regulating ICP27 expression and miRNAs regulatingICP34.5 expression, which provide the VG201 selectivity in tumor cells versus non-tumor normal cells. VG201 also encodes IL12 & IL15/IL15Ra as cytokine payloads to further enhance both innate and adaptive anti-tumor activity.
VG201 is investigated as image guided, intratumoral injections (IT) in two Phase I clinical trials in US & China. And intravenous (IV) administration was approved by NMPA in January of 2024.
A first-in-human, open label, dose escalation trials for patients with advanced solid tumors that progressed after standard of care treatments is recruiting patients in the US at two sites.
Oncolytic Virus (next-generation TTDR backbone)
Oncolysis, immune cell activation
(intravenous) injection
(intratumoral) injection
VG201 is Virogin’s first non-attenuated OV from the TTDR (Transcription Translation Dual Regulation) backbone family to enter the clinic.
We will continue with exploring the safety and efficacy of VG201 as monotherapy and combinations in various tumor types with focus on high unmet medical need populations for an expediated development process. The program is expected to expand into phase 2 clinical trials. Additional studies exploring the IV administration route for VG201 are progressing.
